Brief: Epigenomics AG Says No Operational Reasons For Sharp Decline In Share Price
04/11/2019 20:00
Nov 4 (Reuters) - Epigenomics AG ECXn.DE :
* EPIGENOMICS AG: NO OPERATIONAL REASONS FOR SHARP DECLINE
IN
SHARE PRICE
* SAYS MANAGEMENT OF CO MAKES IT CLEAR THAT THERE ARE NO
OPERATIONAL REASONS FOR CURRENT AND INEXPLICABLE PRICE DECLINE
Source text for Eikon: ID:nEQ8rBdGPa
Further company coverage: ECXn.DE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Epigenomics AG
See all newsU.S. FDA advisers back approval for Guardant's blood-based cancer test (updated)
U.S. FDA advisers back approval for Guardant's cancer test
Brief: Epigenomics Says Closing Of Agreement On The Acquisition Of Almost All Assets And Adjustment Of Guidance For 2023
Brief: Epigenomics AG Says It Entered Into Agreement On The Acquisition Of Almost All Assets With New Day Diagnostics LLC
Brief: Epigenomics Says Chief Scientific Officer Andrew Lukowiak Resigns